Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...

During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...

Observed annually on March 10, National Women and Girls HIV/AIDS Awareness Day (NWGHAAD) 2025 serves as a crucial reminder of ...

Debates over tuberculosis reporting began in the late 19th century, when the bacterial infection was reframed not as a disease of the elite but of the urban poor. New York City was the first in the ...

Hundreds of HIV doctors and researchers have called on the Trump administration to reverse its sweeping aid funding cuts, ...